MedTrace Logo

A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Prostate Cancer

NCT03373006 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-05-25

Study results available
· View outcomes & findings →

Summary

To investigate the utility of fluciclovine F 18 for evaluation for metastatic disease in men undergoing laser focal therapy of prostate cancer and the impact on inclusion for a focal therapy cohort.

Conditions

Interventions

DRUG

Axumin PET/CT

Synthetic amino acid uptake agent injection followed by imaging

Sponsors & Collaborators

  • HALO Diagnostics

    lead INDUSTRY

Principal Investigators

  • John F Feller, MD · Medical Director, Radiation Safety Officer

  • Bernadette M Greenwood, MSc. · Chief Research Officer

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-27
Primary Completion
2020-01-30
Completion
2020-01-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03373006 on ClinicalTrials.gov